Phaco does not boost AMD progression

Article

No clear link between cataract surgery and progressive age-related macular degeneration (AMD) could be established by a study published in the February issue of Ophthalmology.

No clear link between cataract surgery and progressive age-related macular degeneration (AMD) could be established by a study published in the February issue of Ophthalmology.

Emily Y. Chew of the US National Eye Institute, Bethesda, Maryland and colleagues assessed the incidence of advanced AMD development among participants in the Age-Related Eye Disease Study (AREDS). Participants (n=4577; eyes, n=8050) - aged 55–80 years, with a visual acuity of 20/32 or better at baseline - were assessed for geographic atrophy, geographic atrophy of the central macula and neovascular AMD, and a history of cataract surgery was taken at six month intervals for up to 11 years. One thousand, one hundred and sixty-seven participants underwent cataract surgery during the study period.

The Cox proportional hazards model for right and left eyes showed no significant increase of risk for AMD after phacoemulsification. In the right eye, the hazard ratio for geographic atrophy, central geographic atrophy and neovascular AMD were 0.80, 0.87 and 1.20, respectively; in the left eye, these ratios were 0.94, 0.86 and 1.07, respectively. In eyes with pre-existing advanced AMD, the hazard ratios for the fellow eye were 0.98 for central geographic atrophy and 1.08 for neovascular AMD.

Contrary to previous study results, therefore, the team concluded that cataract surgery did not increase the risk of AMD progression significantly.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.